Latest news
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged - TipRanksTipRanks · Sat, 08 Aug 2026 03:23:39 GMTDylan Becker Reiterates Buy on Arlo as Strong Results, Raised Guidance and Growing Subscription Revenue Underscore Attractive Valuation - TipRanksTipRanks · Fri, 07 Aug 2026 11:25:44 GMTXeris Biopharma: Buy Rating Reiterated on Strong Recorlev Momentum and Raised 2026 Outlook; $10 Price Target Maintained - TipRanksTipRanks · Fri, 07 Aug 2026 10:33:21 GMTMayank Tandon Reiterates Buy on Par Technology After Strong Q2 and Raised Outlook, Keeps $25 Price Target Unchanged - TipRanksTipRanks · Fri, 07 Aug 2026 10:30:39 GMTBuy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained - TipRanksTipRanks · Fri, 07 Aug 2026 01:00:30 GMTEvolus: Buy Rating Reiterated on Strong Execution, Raised Guidance and Unchanged $13 Price Target - TipRanksTipRanks · Thu, 06 Aug 2026 19:46:53 GMTDutch Bros Buy Rating Reiterated as Strong Execution Supports Outlook and Unchanged $88 Price Target - TipRanksTipRanks · Thu, 06 Aug 2026 16:41:30 GMTCVS Health: Buy Rating Reiterated as Strong Q2 Results Support Raised Guidance; Price Target Maintained at $106 - TipRanksTipRanks · Thu, 06 Aug 2026 16:14:42 GMT